The LMU Klinikum is the merged hospital complex of the Ludwig Maximilian University of Munich, including the Campus Innenstadt in the city center and the Campus Großhadern in Hadern. The hospital houses more than 2000 beds with 48 clinics, institutes and departments, making it one of the largest hospitals in Europe.

During the past decade, Klinikum der Universitat Munchen conducted 264 clinical trials. In the 10-year time frame, 264 clinical trials started and 107 clinical trials were completed, i.e. on average, 40.5% percent of trials that started reached the finish line to date. In the past 5 years, 113 clinical trials started and 78 clinical trials were completed. i.e. 69% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Klinikum der Universitat Munchen" #1 sponsor was "Boehringer Ingelheim" with 20 trials, followed by "European Organisation for Research and Treatment of Cancer - EORTC" with 16 trials sponsored, "Eli Lilly and Company" with 15 trials sponsored, "Hoffmann-La Roche" with 13 trials sponsored and "Ludwig-Maximilians - University of Munich" with 13 trials sponsored. Other sponsors include 321 different institutions and companies that sponsored additional 179 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Klinikum der Universitat Munchen" #1 collaborator was "Hoffmann-La Roche" with 9 trials as a collaborator, "Eli Lilly and Company" with 8 trials as a collaborator, "AstraZeneca" with 5 trials as a collaborator, "Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)" with 5 trials as a collaborator and "Heart Center Leipzig - University Hospital" with 5 trials as a collaborator. Other collaborators include 269 different institutions and companies that were collaborators in the rest 222 trials.

According to Clinical.Site data, the most researched conditions in "Klinikum der Universitat Munchen" are "Ovarian Cancer" (10 trials), "Chronic Lymphocytic Leukemia" (9 trials), "Leukemia" (9 trials), "Sarcoma" (9 trials) and "Colorectal Cancer" (8 trials). Many other conditions were trialed in "Klinikum der Universitat Munchen" in a lesser frequency.

Most popular intervention types in "Klinikum der Universitat Munchen" are "Drug" (296 trials), "Device" (53 trials), "Biological" (43 trials), "Procedure" (36 trials) and "Other" (35 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (80 trials), "cyclophosphamide" (14 trials), "radiation therapy" (14 trials), "doxorubicin hydrochloride" (12 trials) and "filgrastim" (10 trials). Other intervention names were less common.

The vast majority of trials in "Klinikum der Universitat Munchen" are 375 trials for "All" genders, 22 trials for "Female" genders and 6 trials for "Male" genders.

Currently, there are 144 active trials in "Klinikum der Universitat Munchen". 2 are not yet recruiting, 81 are recruiting, 60 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 180 completed trials in Klinikum der Universitat Munchen, 2 suspended trials, and 53 terminated clinical trials to date.

Out of the total trials that were conducted in Klinikum der Universitat Munchen, 30 "Phase 1" clinical trials were conducted, 125 "Phase 2" clinical trials and 170 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 12 trials, and there were also 43 trials that are defined as “Not Applicable".

Klinikum der Universitat Munchen has several departments that took part in Clinical trials: "Klinikum der Universität München; Campus Großhadern; Med. Klinik und Poliklinik V" - 7 trials, "Department of Psychiatry and Psychotherapy, Ludwig-Maximilian University Munich" - 6 trials, "Klinik für Psychiatrie und Psychotherapie, Ludwig-Maximilians-Universität" - 5 trials, "Klinik und Poliklinik für Dermatologie und Allergologie" - 4 trials, "Medizinische Klinik I- Campus Grosshadern" - 2 trials